Limited and External Funding Opportunities


Research Awards Banner.png

Jump to... 

Contact us...

  • Email LSO@vanderbilt.edu if you are interested in an opportunity not listed below or have questions regarding the LSO submission process.

 


Active Internal Calls for Limited Submission Nominations 

Internal review process required to choose institutional nominees


Limited Submission Eligibility Guidelines

The following tags serve as a guide for submission instructions.

Vanderbilt (VU + VUMC)

  • VU and VUMC submit collaboratively to this LSO. ALL investigators should follow the guidelines posted on this site.

VUMC

  • VU and VUMC submit separately to this LSO. VUMC investigators should follow the guidelines posted on this site. VU investigators should apply through InfoReady and address any questions to VU-LSO@vanderbilt.edu.

FEATURED OPPORTUNITY

  • High-profile or prestigious awards of particular interest to Vanderbilt investigators

2019 V Foundation Pediatric Cancer Research Awards

Vanderbilt (VU + VUMC)     FEATURED OPPORTUNITY

Internal Applications due February 17th 

Vanderbilt (VU + VUMC, collaboratively) has been invited to participate in the V Foundation 2019 Pediatric Cancer Research Grant Program.  Vanderbilt may choose one nominee for the Pediatric Cancer Research Grant Program. The single nominee may apply in either the V Scholar or the Translational program type for support. Last year's guidelines can be viewed here.

Please review each award type below, and submit internal proposals for either program by February 17th. Note that this pediatric call is distinct from the V Foundation “all cancers” call for V Scholars and Translational awards (non-pediatric specific) which has a separate invited call for applications, due March 11th.

Pediatric Cancer Translational Research Award

The V Foundation seeks to support translational research projects within the scope of pediatric cancer research. The Translational Research Award is a $600,000 grant awarded in three annual installments of $200,000. Indirect costs up to a maximum of 10% within the total award are permitted.

Definition of a translational research project: Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new pediatric clinical trial.

Applicant Eligibility:  By April 2, 2019, applicants who will lead this research team must have all the following:

  • Be scientists who hold a tenure-track faculty position (any level) at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination to lead the Translational Research Team.
  • Applicants must be either US citizens or have a legal permit to work in the USA (either temporary or permanent).

Pediatric Cancer V Scholar Award

The Pediatric Cancer V Scholar Award supports young tenure-track faculty early in their cancer research career by funding projects that are either laboratory-based fundamental research or translational research. The total amount of the grant is $200,000 awarded in two annual installments of $100,000, each. No indirect costs are permitted.

Applicant Eligibility: Applicants must have all the following by April 2, 2019:

  1. Hold a tenure-track faculty position as an assistant professor at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for this grant competition.
  2. Have been appointed to their first full-time assistant professor position within the last 5 years, and not yet been promoted to Associate Professor.
  3. Clinical scientists are eligible if their Department can demonstrate that it will fully support the research applicant (e.g., dedicated lab space, start-up funds, dedicated research time).
  4. Applicant can NOT already have been awarded an R01 or R01-equivalent grants. Applicants who have been awarded R01 equivalent grants (Project leader on an NIH multi-investigator grant, ACS) as principal investigators or as co-leader at the time of application submission are not eligible for consideration as a V Scholar. In addition, applicants cannot be a co-leader on a SPORE project or (co)PI of the following NIH grant mechanisms: U01, DP1, DP2, R37, R23.
  5. Applicant must have at least 2 years post-doctoral (MD or PhD) fellowship training. For MDs, a minimum of one year is acceptable if only one year is required for the specialty.
  6. Applicants must be either US Citizens or be a permanent legal resident in the US.

Internal Selection Process:

Anyone interested in being considered as Vanderbilt’s nominee for either of the Pediatric Awards above must submit the following (in PDF format) to LSO@vanderbilt.edu  by 11:59 p.m. on Sunday, February 17th, 2019. Late applications will not be considered.

  • Brief (2 page maximum) research plan including summary budget;
  • Statement of support from department chair/center director;
  • NIH Biosketch or 5-page CV

Submissions should reference the award type (Translational Research Award or V Scholar) in the subject line of the email.  Vanderbilt’s selected applicant will submit a short nomination form by February 28, 2019 and a full application by April 2, 2019.

Please contact us at LSO@vanderbilt.edu if you have any questions about the program, foundation, or internal review process.


NCI Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trial Not Allowed)

VUMC

Internal Applications due February 22nd 

Overview:

VUMC may submit one application to the National Cancer Institute (NCI) Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trial Not Allowed).

This FOA will establish two Pharmacokinetics Resource Laboratories (PK Laboratories) as an infrastructure to support the ETCTN Clinical Sites. PK Laboratories will be responsible for the organization of specimen collection and subsequent analyses of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. PK laboratories should be multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). 

Research Objectives and Main Requirements

The ETCTN PK Laboratory awards will provide the major resource for rapid, efficient, systematic evaluation and determination of the ADME (absorption, distribution, metabolism, and excretion) profiles in patients participating in early phase clinical trials. The ETCTN PK Laboratories will be responsible for establishing pharmacokinetic profiles of NCI-IND anticancer agents and their metabolites in blood. Specific agents (alone and in combinations) will be analyzed for their half-lives and rates of elimination for these investigational agents to ensure the safe and effective therapeutic management of drugs in an individual patient. The ETCTN PK Laboratories will provide:

  • Technical and clinical evaluation of assays for study drug(s) PK that are quality assured/quality controlled and standardized for use in plasma and/or tumor tissue;
  • Evaluation of drug-drug interaction risk for each drug and its active metabolites in relationship to other therapeutics and concomitant medications;
  • Definition of PK sampling strategies, limited sampling strategies and population PK;
  • Evaluation of PK in plasma and tissue; and
  • Timely reporting and analysis to the study team and to NCI of the results of PK analyses.

See the solicitation for a full list of Specific Research Capabilities and Requirements.

Internal Application Process:

Anyone interested in being considered as VUMC’s nominee must submit the following to LSO@vanderbilt.edu by 5 p.m. on February 22, 2019. Please combine your materials into a single PDF and reference the program name in the subject line of the email. 

  • Brief research plan including summary budget (2 page max including budget);
  • Statement of support from department chair/center director;
  • NIH Biosketch for PI

NIH Collaborative Program Grant for Multidisciplinary Teams (RM1)

VUMC

Internal applications due March 8th  

Overview:

VUMC may submit one proposal for the May 2019 cycle of the NIH Collaborative Program Grant for Multidisciplinary Teams (RM1). The program is designed to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important for the mission of National Institute of General Medical Sciences (NIGMS). Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. While applications may request research program budgets of up to $1.5 million direct costs per year, it is anticipated that most awards will be between $700,000-$900,000 direct costs per year.

Applications may address any area of science within the NIGMS mission, which is to support basic research that increases understanding of biological processes at a range of levels, from molecules and cells to tissues, whole organisms and populations. NIGMS also supports research in a limited number of clinical areas that affect multiple organ systems (see here for scientific areas supported by NIGMS).

We recommend that applicants review the RFA in detail to review the research areas that are within the NIGMS mission. Applications that focus solely on a specific organ or disease state and that are within the mission areas of other NIH Institutes and Centers are not appropriate for this FOA. Applications that employ specific cells or tissues to address a fundamental biomedical question are appropriate.

Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies or infrastructure development are not appropriate for this FOA. NIH-defined clinical trials are not allowed.

Internal Application Process:

Anyone interested in being considered to submit VUMC’s proposal must submit the following (in a single PDF) to LSO@vanderbilt.edu by 5 p.m. on Friday, March 8:

  • Brief (2-page maximum) project description including summary budget and role of each PI;
  • Brief statement of support from department chair/center director;
  • NIH Biosketch for all PIs

Full applications are due to NIH by May 25, with an LOI requested 30 days prior. Any questions about this opportunity or the LSO process may be directed to LSO@vanderbilt.edu.


NIBIB Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)

Vanderbilt (VU + VUMC) 

Internal Applications due March 8th 

Overview:

Vanderbilt may submit one application to the ESTEEMED program.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Biomedical Imaging and Bioengineering (NIBIB) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.

This FOA will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities for underrepresented undergraduate freshmen and sophomores in a science, technology, engineering, or mathematics (STEM) field, especially those fields which broadly impact bioengineering. The ESTEEMED program is intended to support underrepresented racial and ethnic groups, individuals with disabilities, and individuals from disadvantaged backgrounds. It will prepare these participants for an Advanced Honors Program, such as a MARC U-STAR (T34) program and institutional program with similar goals, in the junior and senior years and subsequently, to pursue a Ph.D. or M.D./Ph.D. degree and a biomedical research career in academia or industry.

Please read the solicitation for more information.

Internal Application Process:

Interested faculty should visit https://vanderbilt.infoready4.com/#competitionDetail/1782914 to apply for the internal LSO competition. The deadline for the internal competition is Friday, March 8, 2019. Submission materials include the following:

  • Brief (2-page maximum) research plan including summary budget;
  • NIH Biosketch or 5-page CV
  • Statement of support from department chair/center director;

Any questions about this opportunity or the LSO process may be directed to LSO@vanderbilt.edu.


2019 V Foundation V Scholar Awards- All Adult Cancer Research

 Vanderbilt (VU + VUMC)     FEATURED OPPORTUNITY 

Internal Applications due March 11th 

Overview:

Vanderbilt (VU + VUMC, collaboratively) may choose one nominee for the V Foundation V Scholar Award program, which is open to research in all adult cancer types.

The V Foundation aims to “achieve victory over cancer” in part by funding cancer research grants. The V Scholar Award supports early tenure-track faculty by funding a range of projects from laboratory based fundamental research through bench to bedside research. The total amount of the grant is $200,000, paid in two annual installments of $100,000. Only direct costs of the research are supported by this award.

Note that this adult cancers competition is distinct from the V Foundation “pediatric cancers” V Scholars and Translational awards competition, which has an internal application due date of February 17th.

Eligibility:

This call for applications is specifically for adult cancer research.  Additionally, by the application due date (May 6), all of the following must apply:

  • Applications from minority groups underrepresented in science are encouraged, but not required. For this application: African American or of African descent, Hispanic American (non-European) or Native American and/or an Alaskan Native would be included in minority groups
  • Applicants must hold a tenure-track faculty position as an assistant professor. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for this grant competition.
  • Have been appointed to their first full-time assistant professor position within the last 5 years, and not yet been promoted to Associate Professor.
  • Clinical scientists are eligible if their Department can demonstrate that it will fully support the research applicant (e.g., dedicated lab space, start-up funds, dedicated research time).
  • Applicants must have at least 2 years post-doctoral (MD or PhD) fellowship training. For MDs, a minimum of one year is acceptable if only one year is required for the specialty.
  • Applicants must be either US Citizens or be a permanent legal resident in the US.
  • Applicants may NOT already have an R01 or R01-equivalent grant. As of the Due Date of the Application, applicants who have been awarded R01 equivalent grants (Project leader on an NIH multi-investigator grant, ACS) as principal investigators or as co-leader at the time of application submission are not eligible for consideration as a V Scholar. In addition, applicants cannot be a co-leader on a SPORE project or (co)PI of the following NIH grant mechanisms: U01, DP1, DP2, R37, R23. In addition, principal investigators for research project grants (RPGs), analogous to NIH/NCI R01 awards, would also be ineligible.

Internal Selection Process:

Anyone interested in being considered as Vanderbilt’s nominee must submit the following (in PDF format) to LSO@vanderbilt.edu  by 5 p.m. on Monday, March 11, 2019.

  • Brief (2 page maximum) research plan including summary budget;
  • Statement of support from department chair/center director;
  • NIH Biosketch or 5-page CV.

Submissions should reference “2019 V Scholar Award- All Cancer Research” in the subject line of the email. Please contact us at LSO@vanderbilt.edu if you have any questions about the program, foundation, or internal review process.

 


Active Calls for NON-Limited External Opportunities 

Internal review process NOT required- Submit directly to Sponsor


Conquer Cancer Foundation of ASCO: Endowed Young Investigator Award in Mantle Cell Lymphoma

Applications due February 25th 

The Conquer Cancer Foundation of ASCO Endowed Young Investigator Award (YIA) in Mantle Cell Lymphoma (MCL) provides funding to promising investigators to encourage and promote quality clinical research in MCL. The purpose of this award is to fund physicians during the transition from a fellowship program to a faculty appointment. The Conquer Cancer Foundation welcomes application submissions only from investigators who are committed to conducting clinical and translational MCL research. The Young Investigator Award is a one-year grant totaling $50,000. An applicant must be an ASCO member or submit an ASCO membership application with the grant application


Undiagnosed Diseases Network- Gene Function Studies Awards

Proposals due February 28th

The Undiagnosed Diseases Network (UDN), a research project of the NIH Common Fund, has posted a list of genes and variants for additional study and a call for proposals. These are rare and previously undescribed genomic variants for which little or not enough is known about their biological mechanism. The list of eligible genes & variants can be found on the program website.

Applicants would be supported in proposing in depth biological studies beyond screening, such as studies to complement the work performed by the UDN Model Organisms Screening Centers, that probe into mechanisms of disease, provide insight into therapeutic targets, or provide novel insights into the UDN candidate genes.

Applicants must indicate their willingness to share research plans and data with clinicians and investigators in the UDN and participate in network-wide meetings. 

Budgets should not exceed $150,000 total costs and must reflect the actual needs of the proposed project.

If you have any questions please contact the UDN Coordinating Center at Harvard.  Applicants are strongly encouraged to contact the UDN for additional information on variants.  If you have questions about the proposal requirements, please email udncc@hms.harvard.edu.


Cystic Fibrosis Foundation Awards for Gene Editing for Cystic Fibrosis

Applications due March 12th

The Cystic Fibrosis Foundation announces a Request for Applications (RFA) to identify and support highly meritorious proposals in gene editing that offer potential to repair or circumvent CFTR mutations in individuals with CF. The idea for this RFA developed after the Foundation's "CF Gene Editing Workshop: Advancing Gene Editing Technologies and Tools for Cystic Fibrosis" in August 2018. A key concept that emerged from this workshop was that investigators without experience in CF research would be more inclined to become involved in this work if access to CF tools and reagents, as well as CF knowledge, were available.

To bring new technologies to the CF field, investigators without experience in CF research are encouraged to apply. 

There are four award types:

  • Collaborative Award: Up to $75,000 per year (max $250,000) per project per year within the collaborative project plus 8% indirect costs for up to 3 years
  • Pilot and Feasibility Award: Up to $75,000 per year plus 8% indirect costs for up to 2 years
  • Postdoctoral Fellowship Award: First-year fellowship up to $63,100; Second-year fellowship up to $65,450
  • Research Award: Up to $200,000 per year plus 8% indirect costs for up to 3 years

NIGMS Grants Equipment Supplement Program

Applications due March 15th

VUMC faculty who intend to apply should email amy.f.martinez@vumc.org by February 15th­, to facilitate coordination of potentially similar equipment requests (see NOT-GM-19-013)

The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded R01, R35, and R37 awards. These funds are intended for the purchase of single pieces of equipment with requested direct costs up to $250,000.  Equipment in this price range is often difficult to purchase under the parent grant. Two NIGMS grantees at the same institution with similar equipment needs are encouraged to submit separate requests (with a combined budget of not more than $250,000 direct costs) that cross-reference each other. It is expected that the amount of funds requested for such joint purchases will reflect the actual proportion of the time that the shared equipment would be used by each PD/PI.


The Science & PINS Prize for Neuromodulation (Young Investigator Award)

Applications due March 15th

The Science & PINS Prize is awarded for innovative research that modulates neural activity through physical (electrical, magnetic, optical) stimulation of targeted sites in the nervous system with implications for translational medicine. Established in 2016, the prize is administered by Science and Science Translational Medicine and awarded annually for outstanding research as described in a 1,500 word essay based on research performed in the past three years. The winner of the Science & PINS Prize for Neuromodulation is awarded US$25,000 and publication of his or her essay in Science.

The Prize is awarded annually to one young researcher for the most outstanding neuromodulation research conducted by him/her during the past three years. (Entrants must be a Junior Investigator with an advanced degree received in the last 10 years and must be 45 years or younger as of January 1, 2018.)


Craig H. Neilsen Foundation Psychosocial Research Grants

LOIs due March 25

The goal of the portfolio is to develop sound data to inform and disseminate best practices that produce better outcomes, improving quality of life for people living with SCI. This research explores the interrelation of behavioral, social and psychological factors that influence participation, health practice, lifestyle, and support systems in community and clinical settings. 

POSTDOCTORAL FELLOWSHIPS

  • Two-year Postdoctoral Fellowships encourage early-career mentored training to increase professional interest in the field and to encourage researchers from related health disciplines to undertake training in psychosocial research focused on spinal cord injury.

PILOT GRANTS

  • Two-year Pilot Grants support psychosocial research projects that lay the groundwork to inform future studies, that test the feasibility of novel methods, and/or that collect new data that can enhance larger scale studies.

STUDIES AND DEMONSTRATION PROJECTS

  • Three-year Studies and Demonstration Projects encourage innovative and substantive studies that fill important gaps in the spinal cord injury field, that open new areas of psychosocial research, and/or that develop and evaluate interventions to address psychosocial issues after spinal cord injury.

2019 FNIH Trailblazer Prize for Clinician-Scientists

Nominations due March 29th 

The FNIH Trailblazer Prize for Clinician-Scientists (Trailblazer Prize) recognizes the outstanding contributions of early career clinician-scientists whose work has the potential to or has led to innovations in patient care. This $10,000 honorarium and prize celebrates the transformational work of clinician-scientists, whose research translates basic scientific observations into new paradigm-shifting approaches for diagnosing, preventing, treating or curing disease and disability. 

Key eligibility criteria:

• Candidate must be an early-career staff member of a clinical department or unit. We define “early career” as no more than 10 years since the completion of clinical training or 10 years from the completion of their first post-doctoral fellowship (whichever was completed last).

• Candidate must be a practicing clinician with at least 50% of time devoted to independent active research efforts.

• Candidate is nominated for an achievement(s) in basic, translational and/or clinical research leading to new, innovative approaches in the diagnosis, prevention, treatment or cure of diseases and/or disabilities.


Craig H. Neilsen Foundation Spinal Cord Injury Research on the Translational Spectrum

LOIs due May 4th

The Spinal Cord Injury Research on the Translational Spectrum (SCIRTS) portfolio focuses on research designed to improve understanding and advance the current treatment of acute and chronic spinal cord injury. The goal of the portfolio is to address gaps in the field and advance novel approaches to improving function and developing curative therapies after spinal cord injury. The scope of this program is broad, encompassing mechanistic, preclinical modeling, translational and/or clinical research. 

POSTDOCTORAL FELLOWSHIPS

  • Two-year Postdoctoral Fellowships encourage early-career training and specialization in the field of spinal cord injury research.

PILOT RESEARCH GRANTS

  • Two-year Pilot Research Grants help to establish new investigators in the field of spinal cord injury research and support studies by established investigators who are undertaking new directions in their work. These grants cultivate new lines of research and generate essential preliminary data.

SENIOR RESEARCH GRANTS

  • Three-year Senior Research Grants encourage senior-level investigators to expand the scope of their work in targeted studies that will move the field along the translational spectrum. These grants are intended to open new areas of research, fill gaps in the spinal cord injury field and encourage cutting-edge ideas and approaches that have great potential, despite some additional uncertainty.

NIH Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)

Applications due May 1

Note: Only grantees previously funded under RFA-OD-14-003 are eligible to apply.

This RFA invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout and other genetically-engineered mutant mice and related biomaterials. MMRRC strains are held to the highest standards to optimize reproducibility of studies and assure scientific rigor and transparency; all submitted strains are thoroughly reviewed and documented and include additional quality control measures. The Program Director/Principal Investigator (PD/PI) of each MMRRC in addition to the major resource activities is required to develop a small high risk, high return, research pilot project that complements the goals and needs of the MMRRC consortium.  


Methods Development for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R21 Clinical Trial Not Allowed)

Applications due May 25th 

This program supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.


HESI THRIVE Grant – Making Cancer Patient Quality of Life an Active Research Priority

Letters of Intent Due July 1, 2019 

THRIVE, a partner in the 2018 Biden Cancer Initiative, provides seed grants for nonclinical, clinical, and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. THRIVE also supports the development of approaches to avoid or lessen these effects. 

The THRIVE grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions.

Most awards will be within the range of $20,000 - $50,000 over 24 months. Upon agreement to THRIVE award terms, THRIVE will disburse 75% of funds with the remaining provided upon completion of the study milestones


Preannouncement: DoD Autism Research Program

Deadlines & Program Announcements to be posted in March 2019

This pre-announcement aims to allow investigators time to plan and develop applications.  FY19 Austim Research Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  

Clinical Trial Award

Note: nested early-career investigator option has different award criteria as indicated.

Eligibility

  • Investigators at or above the level of Associate Professor (or equivalent) 
  • Nested Early-Career Investigator Option: Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:
    • Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
    • Is no more than 7 years from the receipt of a terminal degree

    • Has the freedom to commit at least 50% time to the project

Key Mechanism Elements

  • Supports research with the potential to have a major impact on the treatment and/or management of ASD.
  • Preliminary data relevant to the proposed clinical trial are required.
  • Pre-application is required; application submission is by invitation only.
  • Nested Early-Career Investigator Option: Supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research.

Funding

  • Maximum funding of $1,000,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
  • Nested Early-Career Investigator Option: Maximum funding of $1,155,000 for direct costs (plus indirect costs); Maximum period of performance is 4 years.

Clinical Translational Research Award

  • Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports early-phase, proof-of-principle clinical trials with the potential to have a major impact on the treatment and/or management of ASD.
  • Preliminary data relevant to the proposed project are required.
  • Pre-application is required; application submission is by invitation only.
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

Idea Development Award

  • Investigators at or above the level of Assistant Professor (or equivalent), or
  • Multiple PI Option: 
  • Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator and receive a separate award. 
  • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.  Preliminary data relevant to the proposed project are required.
  • Pre-application is required; application submission is by invitation only.
  • Clinical trials or applications including a clinical trial aim are not allowed.
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years